Use of a rare disease patient registry in long-term post-authorisation drug studies: a model for collaboration with industry

Affiliations

¹ Adult Cystic Fibrosis Centre, Royal Brompton and Harefield NHS Foundation Trust, London, UK; NHLI Imperial College, London, UK. Electronic address: d.bilton@rbht.nhs.uk.
² UK Cystic Fibrosis Trust, London, UK.
³ MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
⁴ Adult Cystic Fibrosis Centre, Royal Brompton and Harefield NHS Foundation Trust, London, UK; NHLI Imperial College, London, UK.
⁵ Department of Paediatric Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Review

Diana Bilton et al. Lancet Respir Med. 2018 Jul.

. 2018 Jul;6(7):495-496.

doi: 10.1016/S2213-2600(18)30192-9. Epub 2018 May 4.

¹ Adult Cystic Fibrosis Centre, Royal Brompton and Harefield NHS Foundation Trust, London, UK; NHLI Imperial College, London, UK. Electronic address: d.bilton@rbht.nhs.uk.
² UK Cystic Fibrosis Trust, London, UK.
³ MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
⁴ Adult Cystic Fibrosis Centre, Royal Brompton and Harefield NHS Foundation Trust, London, UK; NHLI Imperial College, London, UK.
⁵ Department of Paediatric Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK.

No abstract available

Publication types